心型脂肪酸结合蛋白和钙卫蛋白联合检测在ST段抬高型急性心肌梗死中的应用价值

[目的]观察心型脂肪酸结合蛋白(H-FABP)和钙卫蛋白(S100A/B)联合检测在ST段抬高型急性心肌梗死(STEMI)中的诊断价值。[方法]纳入STEMI患者41例(病例组)和同期非心源性胸痛患者38例(对照组),以酶联免疫吸附实验(ELISA)试剂盒测定所有患者血清H-FABP与S100A/B含量,受试者工作特征曲线(ROC)曲线分析HFABP与S100A/B联合诊断STEMI的价值。[结果]病例组血清H-FABP与S100A/B含量明显高于对照组(P0.05),病例组血清中H-FABP及S100A/B水平呈正相关(P0.05)。单独以H-FABP、S100A/B及联合来诊断STEMI,敏感度分别是81.05%、76.08%和80.67%,特异度分别为70.25%、74.61%及89.27%,曲线下面积分别是0.81、0.77及0.89。[结论] H-FABP、S100A/B在STEMI患者血清中明显增高,并呈正相关性,联合检测有助于STEMI的诊断。

Value of combined measurement of heart-type fatty acid-binding protein and calprotectin in diagnosis of ST segment elevation myocardial infarction

[Objective] To observe the value of combined measurement of heart-type fatty acid-binding protein (H-FABP) and calprotectin (S100A/B) in diagnosis of ST segment elevation myocardial infarction (STEMI).[Methods] A total of 41 patients with STEMI (case group) and 38 patients with non-cardiogenic chest pain (control group) were collected as study individuals. ELISA kit was used to measure the levels of serum H-FABP and S100A/B. The clinical value of combined measurement of H-FABP and S100A/B in diagnosis of STEMI was assessed.[Results] The levels of serum H-FABP and S100A/B in case group were significantly increased compared with control group (P<0.05). In the case group, serum H-FABP level was positively associated with S100A/B level (P<0.05). In the diagnosis of STEMI, H-FABP alone, S100A/B alone, and H-FABP/S100A/B combination had sensitivities of 81.05%, 76.08% and 80.67%, specificities of 70.25%, 74.61% and 89.27%, and areas under the ROC curves of 0.81, 0.77 and 0.89.[Conclusion] Patients with STEMI have significant increases in H-FABP and S100A/B levels, and there is a correlation among them. Combined measurement of H-FABP and S100A/B can increase the value of the diagnosis of STEMI.